Interactions of Amyloidogenic Proteins

NeuroMolecular Medicine

Volumn 4, Issue 1-2, 2003, Pages 49-58

  Giasson, Benoit I ^a   Lee, Virginia M Y ^a,b   Trojanowski, John Q ^a,b  

^a Center for Neurodegenerative Disease Research   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

A peptide; Alzheimer's disease; Amyloid; Parkinson's disease; Synuclein; Tau

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; CONFORMATIONAL TRANSITION; DISEASE ASSOCIATION; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN POLYMERIZATION; PROTEIN PROTEIN INTERACTION; SENILE PLAQUE;

ALPHA-SYNUCLEIN; AMYLOID BETA-PROTEIN; ANIMALS; HUMANS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; NEURONS; POLYMERS; SENILE PLAQUES; SYNUCLEINS; TAU PROTEINS;

EID: 0142200945     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1385/NMM:4:1-2:49     Document Type: Article

References (88)

1. Abe H., Yagishita S., Amano N., et al. (1992) Argyrophilic glial intracytoplasmic inclusions in multiple system atrophy: immunocytochemical and ultrastructural study. Acta Neuropathol. (Berl.) 84, 273-277.
2. Arrasate M., Perez M., Armas-Portela R., and Avila J. (1999) Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations. FEBS Lett. 446, 199-202.
3. Athanassiadou A., Voutsinas G., Psiouri L., et al. (1999) Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am. J. Hum. Genet. 65, 555-558.
4. Bergeron C. and Pollanen M. (1989) Lewy bodies in Alzheimer disease-one or two diseases? Alzheimer Dis. Assoc. Disord. 3, 197-204.
5. Berriman J., Serpell L. C., Oberg K. A., et al. (2003) Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-β structure. Proc. Natl. Acad. Sci. USA 100, 9034-9038.
6. Boller E, Mizutani T., Roessmann U., and Gambetti P. (1980) Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann. Neurol. 7, 329-335.
7. Brée L., Bussière T., Buée-Scherrer V., Delacourte A., and Hof, P. R. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 33, 95-130.
8. Cabin D. E., Shimazu K, Murphy D., et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. J. Neurosci. 22, 8797-8807.
9. Cairns N. J., Atkinson P. F., Hanger D. P., et al. (1997) Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. Neurosci. Lett. 230, 49-52.
10. Conway K. A., Harper J. D., and Lansbury P.T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320.
11. Davidson W. S., Jonas A., Clayton D. F., and George J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449.
12. Ditter S. M. and Mirra S. S. (1987) Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 37, 754-760.
13. Duda J. E., Giasson B. I., Mabon M. E., et al. (2002) Concurrence of α-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. (Berl.) 104, 7-11.
14. Duda J. E., Lee V. M.-Y., and Trojanowski, J. Q. (2000) Neuropathology of synuclein aggregates. J. Neurosci. Res. 61, 121-127.
15. Forman M. S., Lee V. M.-Y., and Trojanowski J. Q. (2000) New insights into genetic and molecular mechanisms of brain degeneration in tauopathies. J. Chem. Neuroanat. 20, 225-244.
16. Forman M. S., Schmidt M. L., Kasturi S., et al. (2002) Tau and α-synuclein pathology in amygdala of parkinsism-dementia complex pateints of Guam. Am. J. Pathol. 160, 1725-1731.
17. Galasko D., Hansen L. A., Katzman R., et al. (1994) Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch. Neurol. 51, 888-895.
18. Gaspar P. and Gray F. (1984) Dementia in idiopathic Parkinson's disease. Aneuropathological study of 32 cases. Acta Neuropathol. (Berl.) 64, 43-52.
19. George J. M., Jin H., Woods W. S., and Clayton D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361-372.
20. Giasson B. I. Forman M. S., Golbe L. I., et al. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300, 636-640.
21. Giasson B. I. and Lee V. M.-Y. (2003) Are ubiquitination pathways central to Parkinson's disease? Cell 114, 1-8.
22. Giasson B. I., Murray I. V., Trojanowski J. Q., and Lee V.M.-Y. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380-2386.
23. Giasson B. I., Uryu K., Trojanowski J. Q., and Lee V.M.-Y. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619-7622.
24. Glenner G. G. (1980) Amyloid deposits and amyloidosis. N. Engl. J. Med. 302, 1283-1292.
25. Goedert M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501.
26. Goedert M., Jakes R., and Crowther R. A. (1999) Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett. 450, 306-311.
27. Goedert M., Jakes R., Spillantini M. G., et al. (1996) Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550-553.
28. Goldberg M. S. and Lansbury P. T. (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2, E115-E119.
29. Götz J., Chen E, van Dorpe J., and Nitsch, R. M. (2001) Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ fibrils. Science 293, 1491-1495.
30. Gutekust C. A., Li S.-H., Yi H., et al. (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19, 2522-2534.
31. Hakim A. M. and Mathieson G. (1979) Dementia in Parkinson disease: a neuropathologic study. Neurology 29, 1209-1214.
32. Hansen L., Salmon D., Galasko D., et al. (1990) The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 40, 1-8.
33. Hardy J. and Gwinn-Hardy K. (1998) Genetic classification of primary neurodegenerative disease. Science 282, 1075-1079.
34. Huntington's Disease Collaborative Group. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
35. Ingram E. M. and Spillantini M. G. (2002) Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol. Med. 8, 555-562.
36. Irizarry M. C., Growdon W., Gomez-Isla T., et al. (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57, 334-337.
37. Ishizawa T., Mattila P., Davies P., Wang D., and Dickson, D. W. (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J. Neuropathol. Exp. Neurol. 62, 389-397.
38. Iwai A., Masliah E., Yoshimoto M., et al. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475.
39. Jakes R., Spillantini M. G., and Goedert M. (1994) Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32.
40. Kampers T., Friedhoff P., Biernat J., Mandelkow E. M., and Mandelkow E. (1996) RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 399, 344-349.
41. Katzman R., Galasko D., Saitoh T., Thal L. J., and Hansen L. (1995) Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Brain Cogn. 28, 259-265.
42. Kelenyi G. (1967) Thioflavin S fluorescent and Congo red anisotropic staining in the histologic demonstration of amyloid. Acta Neuropathol. (Berl.) 7, 336-348.
43. Klement I. A., Skinner P. J., Kaytor M. D., et al. (1998) Ataxin-1 nuclear localization and aggregation: role in polyglumatine-induced disease in SCA1 transgenic mice. Cell 95, 41-53.
44. Klunk W. E., Pettegrew J. W., and Abraham D. J. (1989) Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 37, 1273-1281.
45. Kobayashi K., Miyazu K., Katsukawa K., et al. (1992) Cytoskeletal protein abnormalities in patients with olivopontocerebellar atrophy-an immunocytochemical and Gallyas silver impregnation study. Neuropathol. Appl. Neurobiol. 18, 237-249.
46. Kruger R., Kuhn W., Muller T., et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
47. Ladewig P. (1945) Double-refringence of the amyloid-congo-red-complex in histological sections. Nature 156, 81-82.
48. Lee V. M.-Y., Goedert M., and Trojanoswki, J. Q. (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159.
49. Lee V. M.-Y. and Trojanowski J. Q. (1999) Neurodegenerative tauopathies: human disease and transgenic mouse models. Neuron 24, 507-510.
50. Lewis J., Dickson D. W., Lin W.-L., et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1490.
51. Lewis J., McGowan E., Rockwood J., et al. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402-405.
52. Lippa C. F., Fujiwara H., Mann D. M., et al. (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153, 1365-1370.
53. Lippa C. F., Schmidt M. L., Lee V. M.-Y., and Trojanowski J. Q (1999) Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann. Neurol. 45, 353-357.
54. Markopoulou K., Wszolek Z. K., Pfeiffer R.F., and Chase B. A. (1999) Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. Ann. Neurol. 46, 374-381.
55. Marui W., Iseki E., Ueda K., and Kosaka K. (2000) Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease. J. Neurol. Sci. 174, 81-84.
56. Masliah E., Rockenstein E., Veinbergs I., et al. (2001) beta-Amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. USA 98, 12245-12250.
57. Murayama S., Arima K., Nakazato Y., et al. (1992) Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. 2. Oligodendroglial cytoplasmic inclusions. Acta Neuropathol. (Berl.) 84, 32-38.
58. Murphy D. D., Rueter S. M., Trojanowski J. Q., and Lee V. M.-Y. (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214-3220.
59. Nacharaju P., Lewis J., Easson C., et al. (1999) Accelerated filament formation from tau protein with specific FTDP-17 missense. FEBS Lett. 447, 195-199.
60. Papadimitriou A., Veletza V., Hadjigeorgiou G. M., et al. (1999) Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology 52, 651-654.
61. Papp M. I. and Lantos P. L. (1992) Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J. Neurol. Sci. 107, 172-182.
62. Perry R. H., Irving D., Blessed G., Fairbairn A., and Perry E. K. (1990) Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J. Neurol. Sci. 95, 119-139.
63. Piao Y. S., Hayashi S., Hasegawa M., et al. (2001) Co-localization of alpha-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathol. (Berl.) 101, 285-293.
64. Polymeropoulos M. H., Lavedan C., Leroy E., et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
65. Probst-Cousin S., Bergmann M., Kuchelmeister K., Schroder R., and Schmid K. W. (1996) Ubiquitin-positive inclusions in different types of multiple system atrophy: distribution and specificity. Pathol. Res. Pract. 192, 453-461.
66. Samuel W., Galasko D., Masliah E., and Hansen L. A. (1996) Neocortical lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J. Neuropathol. Exp. Neurol. 55, 44-52.
67. Saudou F., Finbeiner S., Devys D., and Greenberg M. E. (1998) Huningtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
68. Schmidt M. L., Martin J. A., Lee V. M.-Y., and Trojanowski J. Q. (1996) Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathol. (Berl.) 91, 475-481.
69. Selkoe D. J. (2002) The origins of Alzheimer's disease. JAMA 283, 1615-1617.
70. Serpell L. C. (2000) Alzheimer's amyloid fibrils: structure and assembly. Biochim. Biophys. Acta 1502, 16-30.
71. Serpell L. C., Berriman J., Jakes R., Goedert M., and Crowther R. A. (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. USA 97, 4897-4902.
72. Sipe J. D. and Cohen A. S. (2000) Review: history of the amyloid fibril. J. Struct. Biol. 130, 88-98.
73. Souza J. M., Giasson B. I., Lee V. M.-Y., and Ischiropoulos H (2000) Chaperone-like activity of synucleins. FEBS Lett. 474, 116-119.
74. Spillantini M. G., Crowther R. A., Jakes R., et al. (1998a) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208.
75. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M., and Goedert M. (1998b) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469-6473.
76. Spillantini M. G., Schmidt M. L., Lee V. M.-Y., et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
77. Spira P. J., Sharpe D. M., Halliday G., Cavanagh J., and Nicholson G. A. (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49, 313-319.
78. Takeda A., Arai N., Komori T., et al. (1997) Tau immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 234, 63-66.
79. Takeda A., Mallory M., Sundsmo M., et al (1998) Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am. J. Pathol. 152, 367-372.
80. Taylor J. P., Hardy J., and Fischbeck, K. H. (2002) Toxic proteins in neurodegenerative disease. Science 296, 1991-1995.
81. Trojanowski J. Q., Goedert M., Iwatsubo T., et al. (1998) Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death. Differ. 5, 832-837.
82. Trojanowski J. Q. and Lee V. M.-Y. (2000) "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann. N. Y. Acad. Sci. 924, 62-67.
83. Tu P. H., Galvin J. E., Baba M., et al. (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 44, 415-422.
84. Weinreb P. H., Zhen W., Poon A. W., Conway K. A., and Lansbury P. T. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715.
85. Wilson C. A., Doms R. W., and Lee, V. M.-Y. (1999) Intracellular APP processing and Aβ production in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 58, 787-794.
86. Withers G. S., George J. M., Banker G. A., and Clayton D. F. (1997) Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rathippocampal neurons. Brain Res. Dev. Brain Res. 99, 87-94.
87. Wood S. J., Wypych J., Steavenson S., et al. (1999) alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509-19512.
88. Yamazaki M., Arai Y., Baba M., et al. (2000) Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J. Neuropathol. Exp. Neurol. 59, 585-591.